Bakir Valentić

Bakir Valentić

Auto-generated profile, based on publicly available information

Bakir Valentić

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
SFSteven Joel Feigenberg
Steven Joel Feigenberg
FCFrancesca Costabile
Francesca Costabile
CTCeylan Tanes
Ceylan Tanes
KBKyle Bittinger
Kyle Bittinger
RORoderick O’COnnor
Roderick O’COnnor
AFAndrea Facciabene
Andrea Facciabene
Background: Gut microbiota modulation is an emerging strategy to improve cancer therapy outcomes. This study evaluated the safety and therapeutic potential of combining oral vancomycin—a non-absorbed, gut-restricted antibiotic with primary activity against gram-positive bacteria—with stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC). The underlying hypothesis was that vancomycin-induced changes in gut microbiota could enhance the antitumor effects of SBRT. Methods: We conducted a randomized, open-label pilot study in patients with early-stage NSCLC. Patients received oral vancomycin (125 mg, four times daily for 5 weeks, starting 1 week prior to SBRT). Safety, progression-free survival (PFS), overall survival (OS), gut microbiota composition, gut metabolome, and immune responses were evaluated. Results: The combination of vancomycin and SBRT was well tolerated, with no grade 3 or 4 adverse events reported. Vancomycin treatment selectively depleted certain bacterial strains while enriching others, leading to significant restructuring of the gut microbiota and alterations in the gut metabolome, including reductions in short-chain fatty acids and shifts in other important immunomodulatory metabolites. These changes were associated with dendritic cell and T cell activation, suggesting enhanced systemic immune engagement. Patients receiving vancomycin showed improved outcomes, with a PFS HR of 0.42 (95% CI 0.18 to 0.96; p=0.049) and OS HR of 0.38 (95% CI 0.14 to 0.99; p=0.033), compared with controls. Conclusions: This pilot study demonstrates that gut microbiome modulation using a gram-positive-targeting, gut-restricted antibiotic in combination with SBRT is safe and may improve clinical outcomes in early-stage NSCLC. These findings support further investigation of targeted microbiome modulation strategies as adjuvants to immunogenic therapies like radiation. Trial registration number: NCT03546829 .

7 May 2024 in Research Square
Verified
Preprint
Open access
PDF file
RORoddy O'Connor
Roddy O'Connor
BVBakir Valentić
Bakir Valentić
AKAndre Kelly
Andre Kelly
ASAlexander Shestov
Alexander Shestov
ZGZhiyang Gan
Zhiyang Gan
SGSaar Gill
Saar Gill
Activated T cells undergo a metabolic shift to aerobic glycolysis to support the energetic demands of proliferation, differentiation, and cytolytic function. Transmembrane glucose flux is facilitated by glucose transporters (GLUT) that play a vital role in T cell metabolic reprogramming and anti-tumour function. GLUT isoforms are regulated at the level of expression and subcellular distribution. GLUTs also display preferential selectivity for carbohydrate macronutrients including glucose, galactose, and fructose. GLUT5, which selectively transports fructose over glucose, has never been explored as a genetic engineering strategy to enhance CAR-T cells in fructose-rich tumour environments. Fructose levels are significantly elevated in the bone marrow and the plasma of acute myeloid leukaemia (AML) patients. Here, we demonstrate that the expression of wild-type GLUT5 restores T cell metabolic fitness in glucose-free, high fructose conditions. We find that fructose supports maximal glycolytic capacity and ATP replenishment rates in GLUT5-expressing T cells. Using steady state tracer technology, we show that 13C6 fructose supports glycolytic reprogramming and TCA anaplerosis in CAR-T cells undergoing log phase expansion. In cytotoxicity assays, GLUT5 rescues T cell cytolytic function in glucose-free medium. The fructose/GLUT5 metabolic axis also supports maximal migratory velocity, which provides mechanistic insight into why GLUT5-expressing CAR-Ts have superior effector function as they undergo “hit-and-run” serial killing. These findings translate to superior anti-tumour function in a xenograft model of AML. In fact, we found that GLUT5 enhances CAR-T cell anti-tumour function in vivo without any need for fructose intervention. Accordingly, we hypothesize that GLUT5 is sufficient to enhance CAR-T resilience by increasing the cells’ competitiveness for glucose at physiologic metabolite levels. Our findings have immediate translational relevance by providing the first evidence that GLUT5 confers a competitive edge in a fructose-enriched milieu, and is a novel approach to overcome glucose depletion in hostile tumour microenvironments (TMEs).

16 April 2026 in Blood
Verified
Journal Article
Closed access
JDJoseph S Durgin
Joseph S Durgin
SSShin H Seo
Shin H Seo
SKShadab Kazmi
Shadab Kazmi
BVBakir Valentić
Bakir Valentić
CLChloe Leff
Chloe Leff
SGSaba Ghassemi
Saba Ghassemi
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success. Here, we report the single day production of non-activated CAR T-cells engineered to secrete interleukin-18 (IL-18), a pro-inflammatory cytokine that enhances T-cell function. These non-activated CART-IL18 cells exhibit robust anti-tumor efficacy across xenograft models of lymphoma, leukemia, and pancreatic cancer. IL-18 expression enhances the functional advantages of naïve-like non-activated CAR T-cells, resulting in improved persistence, metabolic fitness, and resistance to exhaustion. Single-cell transcriptomic analysis revealed upregulation of IL7R, KLF2, and MCL1, alongside suppression of inhibitory checkpoint genes such as PDCD1, TOX, and HAVCR2. Metabolomic profiling demonstrated enhanced mitochondrial bioenergetics, with increased spare respiratory capacity and accumulation of α-ketoglutarate, malate, and spermine. Functional in vitro and in vivo profiling demonstrated enhanced per-cell cytotoxicity and in vivo durability. We complemented these studies with single-cell transcriptomic and metabolomic analyses to define CAR T-cell biological states beyond what is captured by xenograft tumor clearance. This IL-18-enhanced, activation-free CAR T product offers a clinically actionable platform with the potential to reduce vein-to-vein time while improving product potency and persistence, providing a rationale for clinical testing in patients with tumors refractory to standard CAR T.

22 June 2026 in Nature Immunology
Verified
Journal Article
Open access
CFCaitlin S. Frazee
Caitlin S. Frazee
SCSisi Chen
Sisi Chen
CBCorbett Berry
Corbett Berry
CLCasey S. Lee
Casey S. Lee
RBReid A. Banciella
Reid A. Banciella
CEChristoph T. Ellebrecht
Christoph T. Ellebrecht
Chimeric antigen receptor (CAR) T cell therapy can result in impressive remissions in hematological malignancies, but relapse is common because a minority of infused cells acquire a long-lived, memory-like state. All US Food and Drug Administration-approved CAR T cell products incorporate either 4-1BB or CD28 costimulatory domains, each conferring distinct phenotypic outcomes, but how these signals control early fate decisions is incompletely understood. Here we show that costimulatory domains control memory fate acquisition through asymmetric cell division. CD28 CAR T cells have higher CAR surface expression and enhanced surface proteome asymmetry after the first division, yet paradoxically they show muted transcriptional, epigenetic and metabolic divergence between daughter cells, correlating with reduced long-term persistence. Conversely, 4-1BB CAR T cells have less surface polarization but more pronounced transcriptional, metabolic and epigenetic divergence, yielding proximal effector-prone and distal persistence-prone daughters. Integrating surface proteomics, transcriptomics, metabolomics and chromatin accessibility, we show how costimulatory domains tune asymmetric cell division to shape CAR T cell fate, providing a mechanistic foundation for optimizing cellular immunotherapy.

10 January 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SFSteven J. Feigenberg
Steven J. Feigenberg
FCFrancesca Costabile
Francesca Costabile
CTCeylan Tanes
Ceylan Tanes
KBKyle Bittinger
Kyle Bittinger
RORoddy O’connor
Roddy O’connor
AFAndrea Facciabene
Andrea Facciabene
We present the results of a randomized, open-label pilot study investigating the combination of oral vancomycin and stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC). Our findings highlight vancomycin’s safety, evidenced by the absence of Grade 3 or 4 adverse events, and its potential to enhance the antitumor efficacy of SBRT. The observed enhancement is linked to vancomycin’s modulation of the gut microbiota, which triggers significant metabolic changes and immune activation, thereby contributing to improved progression-free survival (PFS) and overall survival (OS). Patients received vancomycin (125 mg, four times daily for five weeks, starting one week prior to SBRT), which induced restructuring of the gut microbiome and significant changes in the gut metabolome. Key changes included reductions in short-chain fatty acids (SCFAs) and shifts in other immunomodulatory metabolites. These metabolic shifts were associated with the activation of dendritic cells and T cells, creating a pro-inflammatory environment conducive to strengthening SBRT’s antitumor efficacy. The combination of vancomycin and SBRT presents a novel, low-toxicity therapeutic approach for early-stage NSCLC, showing promising initial outcomes. While the results are encouraging, further research with larger cohorts is necessary to verify these findings and elucidate the underlying mechanisms that contribute to the observed clinical benefits. WHAT IS ALREADY KNOWN ON THIS TOPIC: Radiation therapy is a primary treatment for early-stage non-small cell lung cancer and offers excellent local control in early-stage NSCLC, the challenges of regional and distant failures which occur in up to 50% of patients, lead to increased morbidity and mortality. The gut microbiome is increasingly recognized in cancer immunotherapy. RT can induce Immunogenic Cell Death, activating the immune system and promoting abscopal effect to impact untreated lesions. Our previous preclinical studies have shown that antibiotics like vancomycin can modulate these immune effects and enhance RT’s antitumor activity. WHAT THIS STUDY ADDS: This clinical study corroborates our previous preclinical findings by demonstrating the safety of vancomycin and its potential to enhance the antitumor effects of RT, despite the small cohort size. These findings suggest that vancomycin could be strategically used to improve RT outcomes. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: Our findings prompt further investigation into this combined treatment in a larger patient cohort to confirm enhanced progression-free survival and overall survival. Exploring the impact on distal recurrences and applying this strategy to more advanced patient stages could significantly influence future research directions and clinical practices. This approach may also guide policy towards integrating microbiome modulation strategies in standard cancer treatment protocols.